LiGeR HN1 Meets Survival and Response Endpoints

Company Genmab Event Type Phase 3 interim topline Modality EGFR/LGR5 bispecific antibody plus anti-PD-1 Asset Petosemtamab plus pembrolizumab (LiGeR-HN1) Target EGFR; LGR5; PD-1 Disease Area First-line PD-L1-positive recurrent or metastatic head and neck cancer Summary Genmab reported on 28 October that first-line petosemtamab plus pembrolizumab…